OpenResearchAlpha

The International Journal of Lower Extremity Wounds · 19 Nov 2026

Effect of Topical Recombinant Human Epidermal Growth Factor on Short-Term Wound Area Reduction in Chronic Diabetic Foot Ulcers: A Randomized Controlled Trial

Sneha Daffodil Arul John Bosco, Manoharan Gudipati Venkataraman, Deepak Ravi, Babu Subramanian

0
Citations
no database records one yet
0
Citations in 2026
so far
–
Leading author's h-index
no author has a profile yet
9
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Chronic diabetic ulcers are a main complication of diabetes mellitus and frequently require effective treatment to advance wound healing and prevent complications. This study evaluated topical Recombinant Human Epidermal Growth Factor (rhEGF) compared with conventional saline dressing for managing chronic diabetic ulcers. We conducted a randomized controlled trial at a tertiary care teaching hospital from September 2022 to May 2024. A total of 100 patients with diabetic foot ulcers were randomly assigned to receive each topical rhEGF ointment (Group A, n = 50) or conventional saline dressing (Group B, n = 50). Wound size was assessed at baseline, Day 7, and Day 14 using the graph paper method. The primary result was a reduction in wound size. Baseline demographic and clinical variables were comparable among the groups. By Day 14, Group A demonstrated a significantly smaller mean wound size than Group B (5.78 ± 2.64 cm 2 vs 8.33 ± 3.71 cm 2 ; P = .0001). Topical rhEGF was associated with greater short-term reduction in wound surface area compared with conventional saline dressing over 14 days. These findings indicate a potential short-term benefit in wound-area reduction during inpatient treatment; however, complete wound healing, time to healing, recurrence, amputation, graft take, adverse events, and post-discharge outcomes were not assessed. These findings therefore should not be interpreted as evidence of improved overall healing or long-term clinical effectiveness.

What the data shows

  • No database records a citation yet, as is usual for a paper this new.

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (4)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (9)

What it cites, from open citation data, with Crossref's record of each.